Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site.

# KaliVir Immunotherapeutics

## Sitemaps

- [XML Sitemap](https://kalivir.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [main](https://kalivir.com/) - multiple therapies, one virus. KALIVIR is developing cutting edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. LEARN MORE NEWS AND EVENTS November 19, 2025 – KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors READ MORE PRESENTATIONS Novel Vaccinia
- [NEWS](https://kalivir.com/news/) - Nov 19, 2025 KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors DOWNLOAD Oct 1, 2025 KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors DOWNLOAD May 20, 2025 KaliVir
- [LEADERSHIP](https://kalivir.com/leadership/) - KALIVIR is led by an experienced team of experts that have pioneered the field of oncolytic viral immunotherapy for decades. The leadership team’s experience spans across all stages of oncolytic virus development from discovery and translation to global Phase 3 clinical trial and business development. We are also supported by world-renowned scientific and clinical advisors
- [main](https://kalivir.com/homepage-staging/) - multiple therapies, one virus. KALIVIR is developing cutting edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. LEARN MORE NEWS AND EVENTS February 21, 2024 – KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officer READ MORE PRESENTATIONS Novel Vaccinia Enhanced Template (VET) Oncolytic Platform READ MORE
- [PIPELINE](https://kalivir.com/pipeline/) - KALIVIR’S DEVELOPMENT PIPELINE
- [PRESENTATIONS](https://kalivir.com/presentations/) - Oncolytic Virotherapy Summit 2023 Boston, MA “VET3-TGI, a TGF-Beta Targeting Clinical Oncolytic Virus Developed from the VET Platform for Systemic Delivery” SPEAKER : Steve Thorne, PhD see more 15th Annual International Oncolytic Virotherapy Conference 2023 Banff, AB, Canada “Novel Oncolytic Viral Immunotherapy VET3-TGI displays enhanced systemic delivery and inhibits TGF β -signaling while augmenting Type-1
- [PUBLICATIONS](https://kalivir.com/publications/) - DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, Thorne SH, Hinck AP, and Delgoffe GM, An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. J. Exp. Med. 2023 Vol. 220 No. 10 e20230053 see more Li F, Sheng Y, Hou W, Sampath
- [CONTACT](https://kalivir.com/contact/) - get in touchHeadquarters Visit Us:240 Alpha Drive Pittsburgh, PA 15238 Mail Us:info@kalivir.com Phone Us:1.412.435.6730 Drop Us a Line Your Name (required) Your Email (required) Subject Your Message * You accept the terms of the privacy policy
- [OUR APPROACH](https://kalivir.com/our-approach/) - HOW ONCOLYTIC VIRAL IMMUNOTHERAPY WORKS Oncolytic viral immunotherapy utilizes engineered viruses that can preferentially infect and kill cancer cells thereby generating de novo or boosting pre-existing anti-tumor immunity to combat cancer. Most oncolytic viruses are genetically modified to enhance tumor tropism or tumor targeting abilities, so that the virus’ virulence against non-tumor cells are significantly
- [ENHANCED IV DELIVERY](https://kalivir.com/enhanced-iv-delivery/) - THE VACCINIA ENHANCED TEMPLATE (VET™) BACKBONE KALIVIR‘s VET™ backbone uniquely enhances systemic delivery of the virus to cancer cells by using B cells as IV delivery vehicles. One key component of the VET™ backbone is the expression of various chemokine receptors from vaccinia virus. Our chemokine receptor expressing vaccinia virus is able to infect B
- [VET BACKBONE](https://kalivir.com/vet-backbone/) - THE VACCINIA ENHANCED TEMPLATE (VET™) BACKBONE KALIVIR has developed a potent, novel oncolytic platform called the Vaccinia Enhanced Template (VET™). KaliVir’s VET™ Backbone includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and expression of therapeutic transgene in the tumor. VET™ Backbone
- [PRODUCT CANDIDATES](https://kalivir.com/clinical-candidate/) - VET3-TGI: A potent combination of TGF-B inhibition and IL-12 expression derived from the VET™ BACKBONE VET3-TGI builds on the VET™ backbone by adding two therapeutic transgenes encoding IL-12 and a TGF-B inhibitor. TGF-B is known to be a potent suppressor of immune responses and is a major factor in determining the patient response to checkpoint
- [PRIVACY POLICY](https://kalivir.com/privacy-policy/) - CONTENT GOES HERE…
- [DISCLAIMER](https://kalivir.com/disclaimer/) - CONTENT GOES HERE…
- [TERMS OF USE](https://kalivir.com/terms-of-use/) - CONTENT GOES HERE…
- [PARTNERSHIPS](https://kalivir.com/partnerships/) - PARTNERSHIPS KaliVir Immunotherapeutics is committed to developing our pipeline through the establishment of strategic partnerships. For more information or inquiries on collaborations and partnerships, please send an inquiry by clicking below. Your Name (required) Your Email (required) Subject Your Message Partners
- [MISSION](https://kalivir.com/mission/) - KALIVIR is a biopharmaceutical company founded in 2019 dedicated to developing systemically deliverable oncolytic virus immunotherapies. We design a new class of oncolytic virus immunotherapies that combine the natural ability of viruses to kill cancers cell with novel mechanisms to stimulate anti-tumor immunity, modify tumor environment and maximize targeted killing across all tumor types. Our mission is to
- [Home](https://kalivir.com/home-2/) - LEARN MORE
- [Shop](https://kalivir.com/shop/)
- [HOME](https://kalivir.com/home/) - KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This multi-mechanistic treatment modality is known as oncolytic immunotherapy.
- [TERRY HERMISTON, Ph.D.](https://kalivir.com/terry-hermiston/) - Dr. Hermiston has over 20 years of industrial experience in research and drug development. His experience includes drug development mainly focused on idea conception and concept validation and Scientific Advisory Board and Board of Directors service for small biotechnology companies.
- [RICHARD JONES, M.B.A.](https://kalivir.com/richard-jones/) - Rick Jones is a seasoned executive and serves on the board of several companies in addition to Western Oncolytics, including Pegasystems, Inc. and Colo5 LLC. He was a former President, COO, and Vice Chairman at Pegasystems.
- [GREGG BELOFF](https://kalivir.com/gregg-beloff/) - Gregg has more than 20 years of experience in the life science industry, ranging from venture-backed start-ups to publicly traded companies.
- [URSULA FRITSCH](https://kalivir.com/ursula-fritsch/) - Dr. Fritsch has extensive experience in overseeing global regulatory interactions. During her career, she has overseen numerous BLAs, NDAs, INDs and special designation submissions and approvals. 
- [GEORG ROTH](https://kalivir.com/georg-roth/) - [fusion_builder_container admin_label=”” hundred_percent=”no” hundred_percent_height=”no” hundred_percent_height_scroll=”no” hundred_percent_height_center_content=”yes” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”no” status=”published” publish_date=”” class=”” id=”” link_color=”” link_hover_color=”” border_size=”0″ border_color=”” border_style=”solid” margin_top=”” margin_bottom=”” padding_top=”40px” padding_right=”” padding_bottom=”20px” padding_left=”” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”#f0f0f0″ background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_blend_mode=”none” video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” video_preview_image=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″
- [KURT ROTE](https://kalivir.com/kurt-rote/) - [fusion_builder_container admin_label=”” hundred_percent=”no” hundred_percent_height=”no” hundred_percent_height_scroll=”no” hundred_percent_height_center_content=”yes” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”no” status=”published” publish_date=”” class=”” id=”” link_color=”” link_hover_color=”” border_size=”0″ border_color=”” border_style=”solid” margin_top=”” margin_bottom=”” padding_top=”40px” padding_right=”” padding_bottom=”20px” padding_left=”” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”#f0f0f0″ background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_blend_mode=”none” video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” video_preview_image=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″
- [JON WIGGINTON](https://kalivir.com/jon-wigginton/) - [fusion_builder_container admin_label=”” hundred_percent=”no” hundred_percent_height=”no” hundred_percent_height_scroll=”no” hundred_percent_height_center_content=”yes” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”no” status=”published” publish_date=”” class=”” id=”” link_color=”” link_hover_color=”” border_size=”0″ border_color=”” border_style=”solid” margin_top=”” margin_bottom=”” padding_top=”40px” padding_right=”” padding_bottom=”20px” padding_left=”” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”#f0f0f0″ background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_blend_mode=”none” video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” video_preview_image=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″
- [TOM LEONARD](https://kalivir.com/tom-leonard/) - [fusion_builder_container admin_label=”” hundred_percent=”no” hundred_percent_height=”no” hundred_percent_height_scroll=”no” hundred_percent_height_center_content=”yes” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”no” status=”published” publish_date=”” class=”” id=”” link_color=”” link_hover_color=”” border_size=”0″ border_color=”” border_style=”solid” margin_top=”” margin_bottom=”” padding_top=”40px” padding_right=”” padding_bottom=”20px” padding_left=”” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”#f0f0f0″ background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_blend_mode=”none” video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” video_preview_image=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″

## My Templates

- [leadership-Youm](https://kalivir.com/?elementor_library=leadership-youm) - Content Area
- [leadership-Fritsch](https://kalivir.com/?elementor_library=leadership-fritsch) - Content Area
- [leadership-Adina](https://kalivir.com/?elementor_library=leadership-adina) - Content Area
- [leadership-Schond](https://kalivir.com/?elementor_library=leadership-schond) - Content Area
- [leadership-James](https://kalivir.com/?elementor_library=leadership-james) - Content Area
- [leadership-Stephen](https://kalivir.com/?elementor_library=leadership-stephen) - Content Area
- [leadership-Helena](https://kalivir.com/?elementor_library=leadership-helena) - Content Area
- [bio-test](https://kalivir.com/?elementor_library=bio-test) - Content Area
- [leadership](https://kalivir.com/?elementor_library=leadership) - KALIVIR is led by an experienced team of experts that have pioneered the field of oncolytic viral immunotherapy for decades. The leadership team’s experience spans across all stages of oncolytic virus development from discovery and translation to global Phase 3 clinical trial and business development. We are also supported by world-renowned scientific and clinical advisors
- [Default Kit](https://kalivir.com/?elementor_library=default-kit)